1
|
Huffman KE, Li LS, Carstens R, Park H, Girard L, Avila K, Wei S, Kollipara R, Timmons B, Sudderth J, Bendris N, Kim J, Villalobos P, Fujimoto J, Schmid S, Deberardinis RJ, Wistuba I, Heymach J, Kittler R, Akbay EA, Posner B, Wang Y, Lam S, Kliewer SA, Mangelsdorf DJ, Minna JD. Glucocorticoid mediated inhibition of LKB1 mutant non-small cell lung cancers. Front Oncol 2023; 13:1025443. [PMID: 37035141 PMCID: PMC10078807 DOI: 10.3389/fonc.2023.1025443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2022] [Accepted: 01/20/2023] [Indexed: 04/11/2023] Open
Abstract
The glucocorticoid receptor (GR) is an important anti-cancer target in lymphoid cancers but has been understudied in solid tumors like lung cancer, although glucocorticoids are often given with chemotherapy regimens to mitigate side effects. Here, we identify a dexamethasone-GR mediated anti-cancer response in a subset of aggressive non-small cell lung cancers (NSCLCs) that harbor Serine/Threonine Kinase 11 (STK11/LKB1) mutations. High tumor expression of carbamoyl phosphate synthase 1 (CPS1) was strongly linked to the presence of LKB1 mutations, was the best predictor of NSCLC dexamethasone (DEX) sensitivity (p < 10-16) but was not mechanistically involved in DEX sensitivity. Subcutaneous, orthotopic and metastatic NSCLC xenografts, biomarker-selected, STK11/LKB1 mutant patient derived xenografts, and genetically engineered mouse models with KRAS/LKB1 mutant lung adenocarcinomas all showed marked in vivo anti-tumor responses with the glucocorticoid dexamethasone as a single agent or in combination with cisplatin. Mechanistically, GR activation triggers G1/S cell cycle arrest in LKB1 mutant NSCLCs by inducing the expression of the cyclin-dependent kinase inhibitor, CDKN1C/p57(Kip2). All findings were confirmed with functional genomic experiments including CRISPR knockouts and exogenous expression. Importantly, DEX-GR mediated cell cycle arrest did not interfere with NSCLC radiotherapy, or platinum response in vitro or with platinum response in vivo. While DEX induced LKB1 mutant NSCLCs in vitro exhibit markers of cellular senescence and demonstrate impaired migration, in vivo DEX treatment of a patient derived xenograft (PDX) STK11/LKB1 mutant model resulted in expression of apoptosis markers. These findings identify a previously unknown GR mediated therapeutic vulnerability in STK11/LKB1 mutant NSCLCs caused by induction of p57(Kip2) expression with both STK11 mutation and high expression of CPS1 as precision medicine biomarkers of this vulnerability.
Collapse
Affiliation(s)
- Kenneth E. Huffman
- Department of Internal Medicine, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, United States
- Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, United States
| | - Long Shan Li
- Department of Internal Medicine, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, United States
- Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, United States
| | - Ryan Carstens
- Department of Internal Medicine, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, United States
- Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, United States
| | - Hyunsil Park
- Department of Internal Medicine, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, United States
- Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, United States
| | - Luc Girard
- Department of Internal Medicine, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, United States
- Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, United States
| | - Kimberley Avila
- Department of Internal Medicine, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, United States
- Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, United States
| | - Shuguang Wei
- Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, United States
| | - Rahul Kollipara
- Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX, United States
| | - Brenda Timmons
- Department of Internal Medicine, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, United States
- Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, United States
| | - Jessica Sudderth
- Children’s Medical Center Research Institute at University of Texas (UT) Southwestern Medical Center, Dallas, TX, United States
| | - Nawal Bendris
- Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX, United States
| | - Jiyeon Kim
- Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL, United States
- Department of Urology, Department of Cellular and Molecular Physiology, Yale School of Medicine, New Haven, CT, United States
| | - Pamela Villalobos
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - Junya Fujimoto
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - Sandra Schmid
- Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX, United States
| | - Ralph J. Deberardinis
- Children’s Medical Center Research Institute at University of Texas (UT) Southwestern Medical Center, Dallas, TX, United States
| | - Ignacio Wistuba
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - John Heymach
- Department of Thoracic/Head and Neck Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, United States
| | - Ralf Kittler
- Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, United States
- Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX, United States
- Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, United States
| | - Esra A. Akbay
- Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, United States
| | - Bruce Posner
- Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, United States
| | - Yuzhuo Wang
- British Columbia Cancer Center, Vancouver, BC, Canada
| | - Stephen Lam
- British Columbia Cancer Center, Vancouver, BC, Canada
| | - Steven A. Kliewer
- Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, United States
- Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX, United States
| | - David J. Mangelsdorf
- Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, United States
- Department of Pharmacology, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX, United States
| | - John D. Minna
- Department of Internal Medicine, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, United States
- Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, United States
- Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, United States
- Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States
| |
Collapse
|
2
|
Pagano PC, Tran LM, Bendris N, O'Byrne S, Tse HT, Sharma S, Hoech JW, Park SJ, Liclican EL, Jing Z, Li R, Krysan K, Paul MK, Fontebasso Y, Larsen JE, Hakimi S, Seki A, Fishbein MC, Gimzewski JK, Carlo DD, Minna JD, Walser TC, Dubinett SM. Identification of a Human Airway Epithelial Cell Subpopulation with Altered Biophysical, Molecular, and Metastatic Properties. Cancer Prev Res (Phila) 2017; 10:514-524. [PMID: 28754664 DOI: 10.1158/1940-6207.capr-16-0335] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Revised: 05/12/2017] [Accepted: 07/12/2017] [Indexed: 12/20/2022]
Abstract
Lung cancers are documented to have remarkable intratumoral genetic heterogeneity. However, little is known about the heterogeneity of biophysical properties, such as cell motility, and its relationship to early disease pathogenesis and micrometastatic dissemination. In this study, we identified and selected a subpopulation of highly migratory premalignant airway epithelial cells that were observed to migrate through microscale constrictions at up to 100-fold the rate of the unselected immortalized epithelial cell lines. This enhanced migratory capacity was found to be Rac1-dependent and heritable, as evidenced by maintenance of the phenotype through multiple cell divisions continuing more than 8 weeks after selection. The morphology of this lung epithelial subpopulation was characterized by increased cell protrusion intensity. In a murine model of micrometastatic seeding and pulmonary colonization, the motility-selected premalignant cells exhibit both enhanced survival in short-term assays and enhanced outgrowth of premalignant lesions in longer-term assays, thus overcoming important aspects of "metastatic inefficiency." Overall, our findings indicate that among immortalized premalignant airway epithelial cell lines, subpopulations with heritable motility-related biophysical properties exist, and these may explain micrometastatic seeding occurring early in the pathogenesis of lung cancer. Understanding, targeting, and preventing these critical biophysical traits and their underlying molecular mechanisms may provide a new approach to prevent metastatic behavior. Cancer Prev Res; 10(9); 514-24. ©2017 AACRSee related editorial by Hynds and Janes, p. 491.
Collapse
Affiliation(s)
- Paul C Pagano
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
| | - Linh M Tran
- Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.,Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
| | - Nawal Bendris
- Department of Cell Biology, UT Southwestern Medical Center, Dallas, Texas
| | - Sean O'Byrne
- Department of Bioengineering, UCLA, Los Angeles, California
| | - Henry T Tse
- Department of Bioengineering, UCLA, Los Angeles, California
| | - Shivani Sharma
- Department of Chemistry and Biochemistry, UCLA, Los Angeles, California.,California NanoSystems Institute, Los Angeles, California
| | - Jonathan W Hoech
- Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.,Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
| | - Stacy J Park
- Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.,Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
| | - Elvira L Liclican
- Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.,Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
| | - Zhe Jing
- Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.,Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
| | - Rui Li
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
| | - Kostyantyn Krysan
- Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.,Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
| | - Manash K Paul
- Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.,Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
| | - Yari Fontebasso
- Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.,Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
| | - Jill E Larsen
- QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Shaina Hakimi
- Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.,Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
| | - Atsuko Seki
- Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
| | - Michael C Fishbein
- Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
| | - James K Gimzewski
- Department of Chemistry and Biochemistry, UCLA, Los Angeles, California.,California NanoSystems Institute, Los Angeles, California
| | - Dino Di Carlo
- Department of Bioengineering, UCLA, Los Angeles, California.,California NanoSystems Institute, Los Angeles, California.,Jonsson Comprehensive Cancer Center, Los Angeles, California
| | - John D Minna
- Hamon Center for Therapeutic Oncology Research and Departments of Medicine and Pharmacology, UT Southwestern Medical Center, Dallas, Texas
| | - Tonya C Walser
- Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.,Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
| | - Steven M Dubinett
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California. .,Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.,Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.,California NanoSystems Institute, Los Angeles, California.,Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.,Jonsson Comprehensive Cancer Center, Los Angeles, California.,VA Greater Los Angeles Health Care System, Los Angeles, California
| |
Collapse
|
3
|
Chen PH, Bendris N, Hsiao YJ, Reis CR, Mettlen M, Chen HY, Yu SL, Schmid SL. Crosstalk between CLCb/Dyn1-Mediated Adaptive Clathrin-Mediated Endocytosis and Epidermal Growth Factor Receptor Signaling Increases Metastasis. Dev Cell 2017; 40:278-288.e5. [PMID: 28171750 DOI: 10.1016/j.devcel.2017.01.007] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2016] [Revised: 11/15/2016] [Accepted: 01/09/2017] [Indexed: 01/18/2023]
Abstract
Signaling receptors are internalized and regulated by clathrin-mediated endocytosis (CME). Two clathrin light chain isoforms, CLCa and CLCb, are integral components of the endocytic machinery whose differential functions remain unknown. We report that CLCb is specifically upregulated in non-small-cell lung cancer (NSCLC) cells and is associated with poor patient prognosis. Engineered single CLCb-expressing NSCLC cells, as well as "switched" cells that predominantly express CLCb, exhibit increased rates of CME and altered clathrin-coated pit dynamics. This "adaptive CME" resulted from upregulation of dynamin-1 (Dyn1) and its activation through a positive feedback loop involving enhanced epidermal growth factor (EGF)-dependent Akt/GSK3β phosphorylation. CLCb/Dyn1-dependent adaptive CME selectively altered EGF receptor trafficking, enhanced cell migration in vitro, and increased the metastatic efficiency of NSCLC cells in vivo. We define molecular mechanisms for adaptive CME in cancer cells and a role for the reciprocal crosstalk between signaling and CME in cancer progression.
Collapse
Affiliation(s)
- Ping-Hung Chen
- Department of Cell Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
| | - Nawal Bendris
- Department of Cell Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA
| | - Yi-Jing Hsiao
- Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei 10617, Taiwan
| | - Carlos R Reis
- Department of Cell Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA
| | - Marcel Mettlen
- Department of Cell Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA
| | - Hsuan-Yu Chen
- Institute of Statistical Science, Academia Sinica, Taipei 11529, Taiwan
| | - Sung-Liang Yu
- Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei 10617, Taiwan
| | - Sandra L Schmid
- Department of Cell Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
| |
Collapse
|
4
|
Bendris N, Schmid SL. Endocytosis, Metastasis and Beyond: Multiple Facets of SNX9. Trends Cell Biol 2016; 27:189-200. [PMID: 27989654 DOI: 10.1016/j.tcb.2016.11.001] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2016] [Revised: 11/01/2016] [Accepted: 11/03/2016] [Indexed: 11/26/2022]
Abstract
Sorting nexin (SNX)9 was first discovered as an endocytic accessory protein involved in clathrin-mediated endocytosis. However, recent data suggest that SNX9 is a multifunctional scaffold that coordinates membrane trafficking and remodeling with changes in actin dynamics to affect diverse cellular processes. Here, we review the accumulated knowledge on SNX9 with an emphasis on its recently identified roles in clathrin-independent endocytic pathways, cell invasion, and cell division, which have implications for SNX9 function in human disease, including cancer.
Collapse
Affiliation(s)
- Nawal Bendris
- Department of Cell Biology, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
| | - Sandra L Schmid
- Department of Cell Biology, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
| |
Collapse
|
5
|
Bendris N, Stearns CJS, Reis CR, Rodriguez-Canales J, Liu H, Witkiewicz AW, Schmid SL. Sorting nexin 9 negatively regulates invadopodia formation and function in cancer cells. J Cell Sci 2016; 129:2804-16. [PMID: 27278018 DOI: 10.1242/jcs.188045] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2016] [Accepted: 05/26/2016] [Indexed: 01/11/2023] Open
Abstract
The ability of cancer cells to degrade the extracellular matrix and invade interstitial tissues contributes to their metastatic potential. We recently showed that overexpression of sorting nexin 9 (SNX9) leads to increased cell invasion and metastasis in animal models, which correlates with increased SNX9 protein expression in metastases from human mammary cancers. Here, we report that SNX9 expression is reduced relative to neighboring normal tissues in primary breast tumors, and progressively reduced in more aggressive stages of non-small-cell lung cancers. We show that SNX9 is localized at invadopodia where it directly binds the invadopodia marker TKS5 and negatively regulates invadopodia formation and function. SNX9 depletion increases invadopodia number and the local recruitment of MT1-MMP by decreasing its internalization. Together, these effects result in increased localized matrix degradation. We further identify SNX9 as a Src kinase substrate and show that this phosphorylation is important for SNX9 activity in regulating cell invasion, but is dispensable for its function in regulating invadopodia. The diversified changes associated with SNX9 expression in cancer highlight its importance as a central regulator of cancer cell behavior.
Collapse
Affiliation(s)
- Nawal Bendris
- Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX75390, USA
| | - Carrie J S Stearns
- Department of Molecular Medicine, Veterinary Medical Center, Cornell University, Ithaca, NY14853, USA
| | - Carlos R Reis
- Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX75390, USA
| | - Jaime Rodriguez-Canales
- Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX77030, USA
| | - Hui Liu
- Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX77030, USA Department of Pathology, Xuzhou Medical College, Province of Jiangsu, China
| | - Agnieszka W Witkiewicz
- Simmons Cancer Center, Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX390, USA
| | - Sandra L Schmid
- Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX75390, USA
| |
Collapse
|
6
|
Abstract
While targeting experiments carried out on the genes encoding many cell cycle regulators have challenged our views of cell cycle control, they also suggest that redundancy might not be the only explanation for the observed perplexing phenotypes. Indeed, several observations hint at functions of cyclins and CDK inhibitors that cannot be accounted for by their sole role as kinase regulators. They are found involved in many cellular transactions, depending or not on CDKs that are not directly linked to cell cycle control, but participating to general mechanisms such as transcription, DNA repair or cytoskeleton dynamics. In this review we discuss the roles that these alternative functions might have in cancer cell proliferation and migration that sometime even challenge their definition as proliferation markers.
Collapse
Affiliation(s)
- Nawal Bendris
- a Institut de Génétique Moléculaire de Montpellier; CNRS; Montpellier; France; Université Montpellier 2 ; Place Eugène Bataillon; Montpellier , France
| | | | | |
Collapse
|
7
|
Bendris N, Williams KC, Reis CR, Welf ES, Chen PH, Lemmers B, Hahne M, Leong HS, Schmid SL. SNX9 promotes metastasis by enhancing cancer cell invasion via differential regulation of RhoGTPases. Mol Biol Cell 2016; 27:mbc.E16-02-0101. [PMID: 26960793 PMCID: PMC4850029 DOI: 10.1091/mbc.e16-02-0101] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2016] [Revised: 02/22/2016] [Accepted: 02/29/2016] [Indexed: 12/04/2022] Open
Abstract
Despite current advances in cancer research, metastasis remains the leading factor in cancer-related deaths. Here, we identify sorting nexin 9 (SNX9) as a new regulator of breast cancer metastasis. We detected an increase in SNX9 expression in human breast cancer metastases compared with primary tumors and demonstrated that SNX9 expression in MDA-MB-231 breast cancer cells is necessary to maintain their ability to metastasize in a chick embryo model. Reciprocally, SNX9 knockdown impairs the process. In vitro studies using several cancer cell lines derived from a variety of human tumors revealed a role for SNX9 in cell invasion and identified mechanisms responsible for this novel function. We showed that SNX9 controls the activation of RhoA and Cdc42 GTPases and also regulates cell motility via the modulation of well-known molecules involved in metastasis, namely RhoA-ROCK and N-WASP. In addition, we have discovered that SNX9 is required for RhoGTPase-dependent, clathrin-independent endocytosis, and in this capacity, can functionally substitute to the bona fide Rho GAP, GRAF1 (GTPase Regulator Associated with Focal Adhesion Kinase). Together, our data establish novel roles for SNX9 as a multifunctional protein scaffold that regulates, and potentially coordinates, several cellular processes that together can enhance cancer cell metastasis.
Collapse
Affiliation(s)
- Nawal Bendris
- Department of Cell Biology, The University of Texas Southwestern Medical Center, Dallas. 6000 Harry Hines Blvd. Dallas, TX 75390-9039
| | - Karla C Williams
- Translational Prostate Cancer Research Group, London Regional Cancer Program, 790 Commissioners Road East, London ON N6A 4L6, Canada
| | - Carlos R Reis
- Department of Cell Biology, The University of Texas Southwestern Medical Center, Dallas. 6000 Harry Hines Blvd. Dallas, TX 75390-9039
| | - Erik S Welf
- Department of Cell Biology, The University of Texas Southwestern Medical Center, Dallas. 6000 Harry Hines Blvd. Dallas, TX 75390-9039
| | - Ping-Hung Chen
- Department of Cell Biology, The University of Texas Southwestern Medical Center, Dallas. 6000 Harry Hines Blvd. Dallas, TX 75390-9039
| | - Bénédicte Lemmers
- Institut de Génétique Moléculaire de Montpellier, CNRS- Universités Montpellier 1 et 2, Montpellier, France
| | - Michael Hahne
- Institut de Génétique Moléculaire de Montpellier, CNRS- Universités Montpellier 1 et 2, Montpellier, France
| | - H S Leong
- Translational Prostate Cancer Research Group, London Regional Cancer Program, 790 Commissioners Road East, London ON N6A 4L6, Canada
| | - Sandra L Schmid
- Department of Cell Biology, The University of Texas Southwestern Medical Center, Dallas. 6000 Harry Hines Blvd. Dallas, TX 75390-9039
| |
Collapse
|
8
|
Loukil A, Cheung CT, Bendris N, Lemmers B, Peter M, Blanchard JM. Cyclin A2: At the crossroads of cell cycle and cell invasion. World J Biol Chem 2015; 6:346-350. [PMID: 26629317 PMCID: PMC4657123 DOI: 10.4331/wjbc.v6.i4.346] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/14/2015] [Revised: 05/27/2015] [Accepted: 10/13/2015] [Indexed: 02/05/2023] Open
Abstract
Cyclin A2 is an essential regulator of the cell division cycle through the activation of kinases that participate to the regulation of S phase as well as the mitotic entry. However, whereas its degradation by the proteasome in mid mitosis was thought to be essential for mitosis to proceed, recent observations show that a small fraction of cyclin A2 persists beyond metaphase and is degraded by autophagy. Its implication in the control of cytoskeletal dynamics and cell movement has unveiled its role in the modulation of RhoA activity. Since this GTPase is involved in both cell rounding early in mitosis and later, in the formation of the cleavage furrow, this suggests that cyclin A2 is a novel actor in cytokinesis. Taken together, these data point to this cyclin as a potential mediator of cell-niche interactions whose dysregulation could be taken as a hallmark of metastasis.
Collapse
|
9
|
Elkin SR, Bendris N, Reis CR, Zhou Y, Xie Y, Huffman KE, Minna JD, Schmid SL. A systematic analysis reveals heterogeneous changes in the endocytic activities of cancer cells. Cancer Res 2015; 75:4640-50. [PMID: 26359453 DOI: 10.1158/0008-5472.can-15-0939] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2015] [Accepted: 07/22/2015] [Indexed: 11/16/2022]
Abstract
Metastasis is a multistep process requiring cancer cell signaling, invasion, migration, survival, and proliferation. These processes require dynamic modulation of cell surface proteins by endocytosis. Given this functional connection, it has been suggested that endocytosis is dysregulated in cancer. To test this, we developed In-Cell ELISA assays to measure three different endocytic pathways: clathrin-mediated endocytosis, caveolae-mediated endocytosis, and clathrin-independent endocytosis and compared these activities using two different syngeneic models for normal and oncogene-transformed human lung epithelial cells. We found that all endocytic activities were reduced in the transformed versus normal counterparts. However, when we screened 29 independently isolated non-small cell lung cancer (NSCLC) cell lines to determine whether these changes were systematic, we observed significant heterogeneity. Nonetheless, using hierarchical clustering based on their combined endocytic properties, we identified two phenotypically distinct clusters of NSCLCs. One co-clustered with mutations in KRAS, a mesenchymal phenotype, increased invasion through collagen and decreased growth in soft agar, whereas the second was enriched in cells with an epithelial phenotype. Interestingly, the two clusters also differed significantly in clathrin-independent internalization and surface expression of CD44 and CD59. Taken together, our results suggest that endocytotic alterations in cancer cells that affect cell surface expression of critical molecules have a significant influence on cancer-relevant phenotypes, with potential implications for interventions to control cancer by modulating endocytic dynamics.
Collapse
Affiliation(s)
- Sarah R Elkin
- Department of Cell Biology, UT Southwestern Medical Center, Dallas, Texas
| | - Nawal Bendris
- Department of Cell Biology, UT Southwestern Medical Center, Dallas, Texas
| | - Carlos R Reis
- Department of Cell Biology, UT Southwestern Medical Center, Dallas, Texas
| | - Yunyun Zhou
- Department of Clinical Science and Quantitative Biomedical Research Center (QBRC), UT Southwestern Medical Center, Dallas, Texas
| | - Yang Xie
- Department of Clinical Science and Quantitative Biomedical Research Center (QBRC), UT Southwestern Medical Center, Dallas, Texas
| | - Kenneth E Huffman
- The Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, Texas
| | - John D Minna
- The Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, Texas. Departments of Internal Medicine and Pharmacology, UT Southwestern Medical Center, Dallas, Texas
| | - Sandra L Schmid
- Department of Cell Biology, UT Southwestern Medical Center, Dallas, Texas.
| |
Collapse
|
10
|
Cheung CT, Bendris N, Paul C, Hamieh A, Anouar Y, Hahne M, Blanchard JM, Lemmers B. Cyclin A2 modulates EMT via β-catenin and phospholipase C pathways. Carcinogenesis 2015; 36:914-24. [PMID: 25993989 DOI: 10.1093/carcin/bgv069] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2014] [Accepted: 05/06/2015] [Indexed: 12/15/2022] Open
Abstract
We have previously demonstrated that Cyclin A2 is involved in cytoskeletal dynamics, epithelial-mesenchymal transition (EMT) and metastasis. This phenotype was potentiated by activated oncogenic H-Ras. However, the mechanisms governing EMT in these cells have not yet been elucidated. Here, we dissected the pathways that are responsible for EMT in cells deficient for Cyclin A2. In Cyclin A2-depleted normal murine mammary gland (NMuMG) cells expressing RasV12, we found that β-catenin was liberated from the cell membrane and cell-cell junctions and underwent nuclear translocation and activation. Components of the canonical wingless (WNT) pathway, including WNT8b, WNT10a, WNT10b, frizzled 1 and 2 and TCF4 were upregulated at the messenger RNA and protein levels following Cyclin A2 depletion. However, suppression of the WNT pathway using the acetyltransferase porcupine inhibitor C59 did not reverse EMT whereas a dominant negative form of TCF4 as well as inhibition of phospholipase C using U73122 were able to do so. This suggests that a WNT-independent mechanism of β-catenin activation via phospholipase C is involved in the EMT induced by Cyclin A2 depletion. Our findings will broaden our knowledge on how Cyclin A2 contributes to EMT and metastasis.
Collapse
Affiliation(s)
- Caroline T Cheung
- Institut de Génétique Moléculaire de Montpellier, CNRS, France-Université Montpellier 2, France-Université Montpellier 1, Montpellier, France
| | - Nawal Bendris
- Institut de Génétique Moléculaire de Montpellier, CNRS, France-Université Montpellier 2, France-Université Montpellier 1, Montpellier, France, UT Southwestern Medical Center, Department of Cell Biology, Dallas, TX, USA and
| | - Conception Paul
- Institut de Génétique Moléculaire de Montpellier, CNRS, France-Université Montpellier 2, France-Université Montpellier 1, Montpellier, France
| | - Abdallah Hamieh
- INSERM U982, Neuronal and Neuroendocrine Differentiation and Communication, Université de Rouen, Mont-Saint-Aignan, France
| | - Youssef Anouar
- INSERM U982, Neuronal and Neuroendocrine Differentiation and Communication, Université de Rouen, Mont-Saint-Aignan, France
| | - Michael Hahne
- Institut de Génétique Moléculaire de Montpellier, CNRS, France-Université Montpellier 2, France-Université Montpellier 1, Montpellier, France
| | - Jean-Marie Blanchard
- Institut de Génétique Moléculaire de Montpellier, CNRS, France-Université Montpellier 2, France-Université Montpellier 1, Montpellier, France,
| | - Bénédicte Lemmers
- Institut de Génétique Moléculaire de Montpellier, CNRS, France-Université Montpellier 2, France-Université Montpellier 1, Montpellier, France,
| |
Collapse
|
11
|
Bendris N, Loukil A, Cheung C, Arsic N, Rebouissou C, Hipskind R, Peter M, Lemmers B, Blanchard JM. Cyclin A2: a genuine cell cycle regulator? Biomol Concepts 2014; 3:535-43. [PMID: 25436557 DOI: 10.1515/bmc-2012-0027] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2012] [Accepted: 07/26/2012] [Indexed: 01/13/2023] Open
Abstract
Abstract Cyclin A2 belongs to the core cell cycle regulators and participates in the control of both S phase and mitosis. However, several observations suggest that it is also endowed with other functions, and our recent data shed light on its involvement in cytoskeleton dynamic and cell motility. From the transcription of its gene to its posttranslational modifications, cyclin A2 regulation reveals the complexity of the regulatory network shaping cell cycle progression. We summarize our current knowledge on this cell cycle regulator and discuss recent findings raising the possibility that cyclin A2 might play a much broader role in epithelial tissues homeostasis.
Collapse
|
12
|
Bendris N, Cheung CT, Leong HS, Lewis JD, Chambers AF, Blanchard JM, Lemmers B. Cyclin A2, a novel regulator of EMT. Cell Mol Life Sci 2014; 71:4881-94. [PMID: 24879294 DOI: 10.1007/s00018-014-1654-8] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2013] [Revised: 05/16/2014] [Accepted: 05/19/2014] [Indexed: 12/16/2022]
Abstract
Our previous work showed that Cyclin A2 deficiency promotes cell invasion in fibroblasts. Given that the majority of cancers emerge from epithelia, we explored novel functions for Cyclin A2 by depleting it in normal mammary epithelial cells. This caused an epithelial to mesenchymal transition (EMT) associated with loss of cell-to-cell contacts, decreased E-Cadherin expression and increased invasive properties characterized by a reciprocal regulation of RhoA and RhoC activities, where RhoA-decreased activity drove cell invasiveness and E-Cadherin delocalization, and RhoC-increased activity only supported cell motility. Phenotypes induced by Cyclin A2 deficiency were exacerbated upon oncogenic activated-Ras expression, which led to an increased expression of EMT-related transcriptional factors. Moreover, Cyclin A2-depleted cells exhibited stem cell-like properties and increased invasion in an in vivo avian embryo model. Our work supports a model where Cyclin A2 downregulation facilitates cancer cell EMT and metastatic dissemination.
Collapse
Affiliation(s)
- Nawal Bendris
- Institut de Génétique Moléculaire de Montpellier, CNRS, 1919 route de Mende, 34293, Montpellier, France
| | | | | | | | | | | | | |
Collapse
|
13
|
Cheung C, Bendris N, Leong H, Lewis J, Chambers A, Blanchard J, Lemmers B. 199 Novel Functions of Cyclin A2 in Epithelial-Mesenchymal Transition and Metastasis. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71997-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
14
|
Abstract
Cell cycle regulators, such as cyclins, are often upregulated in many proliferative disorders, and Cyclin A2 is generally considered as a marker of aggressive cancers. Our recent work, which revealed decreased expression of Cyclin A2 upon metastasis of colorectal cancer, suggests a more complicated situation. Consistent with this, we identified a role for Cyclin A2, via RhoA, in regulation of the actin cytoskeleton and the control of cell invasion. Cyclin A2 also regulates spindle orientation which, when misoriented, could disrupt cell polarity and favor cancer cell detachment from the tumor as part of a transforming process, such as epithelial to mesenchymal transition (EMT). During EMT, cells undergo morphological and molecular changes toward a mesenchymal phenotype. Upregulation, or increased activity of some Rho GTPases, such as Cdc42, Rac1 or RhoC, increases the invasive potential of these cells. This correlates with the inverse relationship between RhoA and RhoC activities we observed in an epithelial cell type. Altogether, these observations raise the possibility that Cyclin A2 is instrumental in preventing EMT and therefore cancers of epithelial tissues.
Collapse
|
15
|
Arsic N, Bendris N, Peter M, Begon-Pescia C, Rebouissou C, Gadéa G, Bouquier N, Bibeau F, Lemmers B, Blanchard JM. A novel function for Cyclin A2: control of cell invasion via RhoA signaling. ACTA ACUST UNITED AC 2012; 196:147-62. [PMID: 22232705 PMCID: PMC3255987 DOI: 10.1083/jcb.201102085] [Citation(s) in RCA: 95] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Cyclin A2 plays a key role in cell cycle regulation. It is essential in embryonic cells and in the hematopoietic lineage yet dispensable in fibroblasts. In this paper, we demonstrate that Cyclin A2-depleted cells display a cortical distribution of actin filaments and increased migration. These defects are rescued by restoration of wild-type Cyclin A2, which directly interacts with RhoA, or by a Cyclin A2 mutant unable to associate with Cdk. In vitro, Cyclin A2 potentiates the exchange activity of a RhoA-specific guanine nucleotide exchange factor. Consistent with this, Cyclin A2 depletion enhances migration of fibroblasts and invasiveness of transformed cells via down-regulation of RhoA activity. Moreover, Cyclin A2 expression is lower in metastases relative to primary colon adenocarcinoma in matched human tumors. All together, these data show that Cyclin A2 negatively controls cell motility by promoting RhoA activation, thus demonstrating a novel Cyclin A2 function in cytoskeletal rearrangements and cell migration.
Collapse
Affiliation(s)
- Nikola Arsic
- Institut de Génétique Moléculaire de Montpellier, Centre National de la Recherche Scientifique, 34293 Montpellier, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Bendris N, Lemmers B, Blanchard JM, Arsic N. Cyclin A2 mutagenesis analysis: a new insight into CDK activation and cellular localization requirements. PLoS One 2011; 6:e22879. [PMID: 21829545 PMCID: PMC3145769 DOI: 10.1371/journal.pone.0022879] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2011] [Accepted: 07/06/2011] [Indexed: 11/24/2022] Open
Abstract
Cyclin A2 is essential at two critical points in the somatic cell cycle: during S phase, when it activates CDK2, and during the G2 to M transition when it activates CDK1. Based on the crystal structure of Cyclin A2 in association with CDKs, we generated a panel of mutants to characterize the specific amino acids required for partner binding, CDK activation and subcellular localization. We find that CDK1, CDK2, p21, p27 and p107 have overlapping but distinct requirements for association with this protein. Our data highlight the crucial importance of the N-terminal α helix, in conjunction with the α3 helix within the cyclin box, in activating CDK. Several Cyclin A2 mutants selectively bind to either CDK1 or CDK2. We demonstrate that association of Cyclin A2 to proteins such as CDK2 that was previously suggested as crucial is not a prerequisite for its nuclear localization, and we propose that the whole protein structure is involved.
Collapse
Affiliation(s)
- Nawal Bendris
- Institut de Génétique Moléculaire de Montpellier, Centre National de la Recherche Scientifique, Université Montpellier 2, Université Montpellier 1, Montpellier, France
| | - Bénédicte Lemmers
- Institut de Génétique Moléculaire de Montpellier, Centre National de la Recherche Scientifique, Université Montpellier 2, Université Montpellier 1, Montpellier, France
| | - Jean-Marie Blanchard
- Institut de Génétique Moléculaire de Montpellier, Centre National de la Recherche Scientifique, Université Montpellier 2, Université Montpellier 1, Montpellier, France
- * E-mail: (JMB); (NA)
| | - Nikola Arsic
- Institut de Génétique Moléculaire de Montpellier, Centre National de la Recherche Scientifique, Université Montpellier 2, Université Montpellier 1, Montpellier, France
- * E-mail: (JMB); (NA)
| |
Collapse
|
17
|
Arsic N, Bendris N, Lemmers B, Peter M, Begon C, Rebouissou C, Bibeau F, Blanchard J. R6: Cycline A2, un nouvel acteur de l’invasion tumorale. Bull Cancer 2010. [DOI: 10.1016/s0007-4551(15)30923-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
18
|
Tousignant M, Habimana E, Biron C, Malo C, Sidoli-LeBlanc E, Bendris N. The Quebec Adolescent Refugee Project: psychopathology and family variables in a sample from 35 nations. J Am Acad Child Adolesc Psychiatry 1999; 38:1426-32. [PMID: 10560230 DOI: 10.1097/00004583-199911000-00018] [Citation(s) in RCA: 98] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE This study presents the results of a psychiatric epidemiological survey using a sample of adolescents from refugee families. METHOD The sample included 203 adolescents, aged 13 to 19 years, coming from 35 countries. Psychopathology was assessed with the Diagnostic Interview Schedule for Children Version 2.25 and general functioning with the Children's Global Assessment Scale (CGAS). RESULTS The total rate of psychopathology excluding simple phobia was 21% compared with 11% in a province-wide survey of young adolescents. Overanxious disorder had a high prevalence of 13%. The rates of major depression and conduct disorders were also high, at 5% and 6%. The rate of 3% of attempted suicide was similar to the rate found in Montreal high schools. Girls had a higher rate of psychopathology than boys, with a gender ratio similar to the one found in the provincial survey. Father's long-term unemployment in the first year of settlement was associated with psychopathology for the whole sample, and family structure was associated with psychopathology for boys only. CONCLUSIONS The high rate of psychopathology in this group confirmed results from other surveys with similar samples. On the other hand, the CGAS scores indicated that many of the adolescents with a diagnosis had good social adaptation.
Collapse
Affiliation(s)
- M Tousignant
- Research Laboratory in Human and Social Ecology, University of Quebec, Montreal, Canada.
| | | | | | | | | | | |
Collapse
|
19
|
Planques Y, Bendris N, Allary M, Lacoste-Bourgeacq JF. [Removal of plasma lipids by selective filtration]. Rev Fr Transfus Hemobiol 1992; 35:95-105. [PMID: 1637422 DOI: 10.1016/s1140-4639(05)80110-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
We herein describe a new depth filter media which exhibits selective adsorption properties for lipids of plasma on Zeta Plus Del I (Cuno Europe). Lipids plug chromatographic columns and filter during plasma fractionnation and cause solution instability for the final product. Several parameters which could affect the lipid removal efficiency on Zeta Plus Del I have been investigated: prefiltration, contact time, ionic strength, pH, and temperature. The maximum percentage of total lipids eliminated, in the better operating conditions was 68%. This method has proven to be efficient for the treatment of plasmatic lipids and can be easily incorporated in an industrial process.
Collapse
|